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Abstract 
Background: Approximately 50% of non-small cell lung cancer (NSCLC) patients with acquired 
resistance to EGFR-TKI harbor the EGFR mutation T790M. The recent development and wide use of 
third-generation EGFR-TKIs targeting T790M-mutant NSCLCs have increased the importance of 
rebiopsy after EGFR-TKI failure. We aimed to investigate the advantages of flexible bronchoscopy as a 
rebiopsy method and the prevalence of and factors affecting the T790M mutation after EGFR-TKI failure. 
Methods: We investigated 139 patients who had undergone bronchoscopic rebiopsy and endobronchial 
ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) between Sep 2014 and Jul 2016. 
Results: Among the 139 patients, bronchoscopic rebiopsy yielded successful pathological diagnoses in 
102 (73.4%). Among them, 41 patients with EGFR-mutant lung adenocarcinoma and EGFR-TKI 
progression were selected for an investigation of T790M mutation prevalence at rebiopsy. The initial 
EGFR mutations were exon 19 del (56.1%), L858R or L861Q (34.1%), and others (9.8%). The most 
common rebiopsy method was transbronchial lung biopsy (41.5%), followed by EBUS-TBNA (26.8%) and 
endobronchial biopsy (19.5%). The median interval to T790M emergence was the longest among cases 
with exon 19 deletion (14.1 months), followed by exon 21 L858R or L861Q (11.3 months) and other rare 
EGFR mutations (2.9 months). The T790M mutation was identified in 18 (43.9%) patients, and exon 19 del 
was the most significant factor affecting T790M mutation development (hazard ratio: 6.875, P = 0.014).  
Conclusions: Bronchoscopy was more useful than other rebiopsy approaches. The T790M emergence 
rate was highest in cases with exon 19 deletion, likely as a consequence of long-term EGFR-TKI exposure. 
Key words: rebiopsy, T790M, epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), non-small 
cell lung cancer (NSCLC) 
Introduction 
Recently, our understanding of non-small cell 
lung cancer (NSCLC), the leading cause of 
cancer-related mortality worldwide[1], and its 
treatment has evolved dramatically, largely due to a 
better understanding of the underlying genomic 
alterations. Currently, mutations in epidermal growth 
factor receptor (EGFR)[2, 3] are the best-described of 
these alterations, and targeted EGFR-tyrosine kinase 
inhibitors (EGFR-TKI) have yielded dramatic 
responses with reduced toxicity in patients with 
EGFR-mutant NSCLC[4]. However, virtually all 








EGFR-TKI treatment for less than 1 year, after which 
drug resistance develops[5].  
Several resistance mechanisms have been 
identified. Of these, the EGFR c.2369C>T (T790M) 
mutation within exon 20 is most prevalent, accounting 
for approximately 50% of EGFR-mutated tumors with 
acquired erlotinib or gefitinib resistance[6]. Recently 
developed third-generation EGFR-TKIs that target 
T790M are effective against NSCLCs harboring this 
mutation and are now widely used in clinical 
settings[7]. These new treatment options have 
increased the importance of rebiopsy for treatment 
guidance in patients with progressive disease and a 
previous history of EGFR-TKI therapy. However, 
several factors limit the feasibility of rebiopsy and 
molecular analysis, including the amount of required 
material, access to the tumor site, and the invasiveness 
of sampling methods, particularly surgical 
rebiopsy[8-10]. 
Therefore, we aimed to investigate the 
advantages of rebiopsy via flexible bronchoscopy. 
This technique is commonly used, minimally 
invasive, and can collect abundant tissue samples for 
histological and molecular analyses. Furthermore, we 
aimed to investigate the prevalence of T790M 
mutation after EGFR-TKI failure, as well as factors 
affecting the T790M mutation rate. 
Methods 
Study design and patients 
This was a single center, observational, 
retrospective study conducted at Severance Hospital 
(Seoul, Republic of Korea), a university-affiliated 
tertiary care referral hospital. The study protocol was 
approved by the Severance hospital institutional 
review board (IRB No. 4-2016-1100). 
We investigated 140 patients who had 
undergone rebiopsy via flexible bronchoscopy 
(endobronchial biopsy and transbronchial lung 
biopsy (TBLB)) and endobronchial ultrasound-guided 
transbronchial needle aspiration (EBUS-TBNA) 
between September 2014 and July 2016. After 
excluding 1 patient with a de novo T790M mutation, 
139 patients remained. We investigated the practical 
success rate (number of patients in which tumor cells 
were detected/total number of rebiopsy cases 
performed x 100 as defined elsewhere[11]) and the 
procedure-related complication rate.  
We additionally selected a subgroup of 41 
patients to investigate the T790M mutation prevalence 
and determine the factors affecting T790M detection. 
The selected patients had pathologically confirmed 
lung adenocarcinoma, known EGFR mutations in 
pre-EGFR-TKI treatment tumor specimens, a history 
of EGFR-TKI therapy, and available rebiopsy tumor 
specimens for EGFR mutation status assessment 
(Figure 1).  
EGFR mutation analysis 
Genomic DNA was purified from 
formalin-fixed, paraffin-embedded sections of tumors 
using the ReliaPrepTM FFPE gDNA Miniprep system 
(Promega, Madison, WI, USA). EGFR mutations were 
detected by the Peptide Nucleic Acid (PNA) real-time 
PCR assay using PNA ClampTM EGFR mutation 
detection kit (Panagene, Daejeon, Republic of Korea). 
 
 
Figure 1. Study design and inclusion and exclusion criteria. 




Data collection and study endpoints 
The analyzed clinical data included age, sex, 
smoking status, performance status (Eastern 
Cooperative Oncology Group; ECOG), EGFR 
mutation status, EGFR-TKI treatment status and 
response, progression-free survival (PFS), and 
rebiopsy condition and method. These data were 
collected retrospectively from medical records. PFS 
was calculated as the interval between the date of 
treatment initiation and the date of progression on 
EGFR-TKI treatment. Unidimensional measurement, 
as defined by the Response Evaluation Criteria in 
Solid Tumors (Version 1.1), was implemented in this 
study[12]. The primary endpoints were the practical 
success rate of rebiopsy by flexible bronchoscopy and 
the prevalence of T790M mutations among 
post-EGFR-TKI rebiopsies. The secondary endpoints 
were the factors influencing T790M mutation 
detection. 
Statistical analysis 
A univariate analysis (χ2 test or Fisher’s exact 
test) of the T790M mutation frequency was conducted 
to evaluate the effects of clinical factors. We 
considered two aspects regarding rebiopsy timing: 1) 
whether patients had received treatment other than 
EGFR-TKI between the first EGFR-TKI progression 
and rebiopsy; those who had received such treatment 
were defined as “with interval from first EGFR-TKI 
progression”, and vice versa. 2) Whether patients 
continued to receive EGFR-TKI treatment within 1 
month before rebiopsy; those who continued 
receiving such treatment were defined as “with 
EGFR-TKI treatment at rebiopsy”, and vice versa. The 
effects of clinical factors on the T790M mutation rate 
were evaluated using a multiple logistic regression 
model. A two-sided P value of <0.05 was considered 
to indicate statistical significance. Statistical analyses 
were performed using the SPSS software package 
(ver. 20.0; SPSS. Inc., Chicago, IL, USA). 
Results 
Patient demographics and features of 
bronchoscopic rebiopsy 
Regarding histology, of the 139 enrolled patients, 
115 (82.7%), 18 (12.9%), 1 (0.7%), and 5 (3.6%) patients 
had adenocarcinoma, squamous cell carcinoma, large 
cell carcinoma, and small cell carcinoma, respectively. 
We successfully obtained the tumor tissues and 
pathologic diagnoses of 102 patients, for an overall 
practical success rate of 73.4%. Only 1 patient 
developed a complication after rebiopsy. Although he 
experienced a bleeding event during transbronchial 
lung rebiopsy, he was discharged without any 
problems. 
Next, we selected 41 patients for the with EGFR 
mutation status subgroup analysis, as described in the 
Methods (Figure 1). The baseline characteristics of this 
subgroup, including the EGFR-TKI treatment and 
rebiopsy statuses, are shown in Table 1. The median 
patient age in the subgroup was 61 years (range: 
26–80 years). Twenty-six patients (63.4%) were 
female, and 31 (75.6%) were never-smokers. Exon 19 
deletion was the most common type of EGFR 
mutation (56.1%), followed by exon 21 L858R or 
L861Q (34.1%). Another 4 patients (9.8%) harbored 
other rare EGFR mutations, including Exon 18 G719X, 
Exon 20 S768I, and two E20 insertion/duplication 
mutations. The median duration of EGFR-TKI 
treatment was 10 months (range: 0.5–35 months). 
 
Table 1. Demographic data and characteristics of EGFR mutant 
adenocarcinoma patients. 
Characteristics n = 41 
Age, median (range) (years) 61 (26-80) 
Gender, n (%)  
 Male 15 (36.6) 
Female 26 (63.4) 
Smoking status, n (%)  
 Never smokers 31 (75.6) 
Former and current smokers 10 (24.4) 
Baseline EGFR mutations, n (%)  
 Exon 19 deletions 23 (56.1) 
Exon 21 L858R or L861Q 14 (34.1) 
Othersa 4 (9.8) 
Initial EGFR-TKI regimen, n (%)  
 Gefitinib 32 (78.0) 
Erlotinib 4 (9.8) 
Afatinib 4 (9.8) 
Dacomitinib 1 (2.4) 
Line of initial EGFR-TKI treatment, n (%)  
 First line 28 (68.3) 
Second line or later 13 (31.7) 
Total EGFR-TKI(s) treatment, n (%)  
 1 39 (95.1) 
2 or moreb 2 (4.9) 
Rebiopsy timing-1, n (%)  
 At first EGFR-TKI PD 22 (53.7) 
With interval from first EGFR-TKI PD 19 (46.3) 
Rebiopsy timing-2, n (%)  
 With EGFR-TKI treatment at rebiopsy 17 (41.5) 
Without EGFR-TKI treatment at rebiopsy 24 (58.5) 
Rebiopsy methods, n (%)  
 TBLB 17 (41.5) 
EBUS-TBNA 11 (26.8) 
Endobronchial biopsy 8 (19.5) 
TBLB + EBUS-TBNA 3 (7.3) 
Endobronchial biopsy + EBUS-TBNA 2 (4.9) 
ECOG, eastern cooperative oncology group; EGFR, epidermal growth factor 
receptor; TKI, tyrosine kinase inhibitor; PD, progressive disease; TBLB, 
transbronchial lung biopsy; EBUS-TBNA, endobronchial ultrasound transbronchial 
aspiration. 
a Other mutations included Exon 18 G719X, Exon 20 S768I, and two E20 
insertion/duplication mutations. 
b Include gefitinib and then afatinib, erlotinib and then gefitinib 
 
 




Gefitinib was the most commonly used 
EGFR-TKI (78.0%). Most subgroup patients (68.3%) 
received EGFR-TKI as the first line of therapy, and the 
majority (95.1%) received only one EGFR-TKI. 
Rebiopsy was performed at the time of the first 
EGFR-TKI progression in 22 patients (53.7%), and 
within a median 2-month (range: 2–34 months) 
interval after the first EGFR-TKI progression in 19 
patients (46.3%). At the time of rebiopsy, 17 patients 
(41.5%) continued receiving EGFR-TKI treatment, 
whereas the other 24 ceased EGFR-TKI use. 
Regarding the rebiopsy method, 17 (41.5%), 11 
(26.8%), 8 (19.5%), 3 (7.3%), and 2 (4.9%) patients 
underwent TBLB, EBUS-TBNA, endobronchial 
biopsy, TBLB with EBUS-TBNA, and endobronchial 
biopsy with EBUS-TBNA, respectively. 
EGFR T790M mutation status at rebiopsy 
Eighteen (43.9%) of the rebiopsy specimens from 
the 41 patients with EGFR mutant adenocarcinoma 
were found to be positive for the T790M mutation. All 
18 patients acquired the T790M mutation along with 
original EGFR mutations; in other words, none had 
newly acquired the T790M mutation without an 
original EGFR mutation. Of the remaining 23 patients, 
18 (43.9%) had only the original EGFR mutation, and 5 
patients (12.2%) had lost the activating EGFR 
mutation at the time of rebiopsy. Next, we 
investigated the frequency of T790M among the 
rebiopsies and observed differences in the rate of 
EGFR T90M emergence according to the initial EGFR 
mutation status. The T790M emergence rate was 
highest among cases with exon 19 deletion (65%), 
followed by exon 21 L858R or L861Q mutation 
(21.5%), but was not associated with other rare EGFR 
mutations (P = 0.002). The median interval to T790M 
emergence was the longest among cases with exon 19 
deletion (14.1 months), followed by exon 21 L858R or 
L861Q (11.3 months) and other rare EGFR mutations 
(2.9 months). Loss of the activating EGFR mutation 
was not observed in Exon 19 deletions (Figure 2). 
Factors affecting the emergence of EGFR 
T790M mutation 
Next, univariate analyses of the patients’ 
characteristics and conditions related to EGFR-TKI 
treatment were performed to identify factors affecting 
the emergence of the T790M mutation (Table 2). Age, 
sex, and smoking status were not found to associate 
significantly with the emergence of the T790M 
mutation. Patients with exon 19 deletions at the initial 
biopsy had a higher T790M mutation rate than did 
those with exon 21 L858R or L861Q mutations and 
others (P = 0.002). Of note, EGFR-TKI-treated patients 
who exhibited better responses (partial response vs. 
stable or progressive disease) to the initial treatment 
tended to have a higher T790M mutation rate, 




Figure 2. Comparison of EGFR mutation status at initial biopsy and rebiopsy. T790M was most prevalent in initial Exon 19 deletions compared to Exon 21 L858R or 
861Q mutations and other rare mutations (P=0.002 by χ2 test). Mean duration of disease progression after EGFR-TKI treatment was 14.1 months in initial Exon 19 
deletions, 11.3 months in initial Exon 21 L858R or 861Q mutations, and 2.9 months in initial other rare EGFR mutations (P = 0.028 by one-way ANOVA test). *Other 
rare mutations included Exon 18 G719X, Exon 20 S768I, and two E20 insertion/duplication mutations. 




Table 2. Univariate analysis of the association of EGFR T790M 
mutation with patient characteristics and the condition of 
EGFR-TKI treatment 
Characteristics N T790M 
mutation (%) 
P value 
Age (years)   0.358 
 < 60 17 9 (52.9)  
≥ 60 24 9 (37.5)  
Gender   0.433 
 Male 15 7 (46.7)  
Female 26 11 (42.3)  
Smoking status   0.482 
 Never smokers 31 13 (41.9)  
Former and current smokers 10 5 (50.0)  
Baseline EGFR mutations   0.002 
 Exon 19 deletions 23 15 (65.2)  
Exon 21 L858R or L861Q 14 3 (21.4)  
Othersa 4 0 (0)  
Initial EGFR-TKI regimen   0.185 
 Gefitinib 32 16 (50.0)  
Erlotinib 4 0 (0)  
Afatinib 4 2 (50.0)  
Dacomitinib 1 0 (0)  
Line of initial EGFR-TKI treatment   0.415 
 First line 28 14 (50.0)  
Second line or later 13 4 (30.8)  
Response to first EGFR TKI   0.075 
 PR 30 16 (53.3)  
SD or PD 11 2 (18.2)  
Total EGFR-TKI(s) treatment   1.000 
 1 39 17 (43.6)  
2 or more b 2 1 (50.0)  
ECOG, eastern cooperative oncology group; EGFR, epidermal growth factor 
receptor; TKI, tyrosine kinase inhibitor; PR, partial response; SD, stable disease; PD, 
progressive disease. 




We also performed univariate analyses 
regarding the rebiopsy conditions and rebiopsy 
methods (Table 3), and found that the target lesion 
size and rebiopsy site did not significantly influence 
the T790M mutation rate (P = 0.551 and P = 0.123, 
respectively). As noted earlier, two aspects of 
rebiopsy timing were considered: whether the patient 
had received treatment other than EGFR-TKI between 
the first EGFR-TKI progression and rebiopsy, and 
whether the patient continued receiving EGFR-TKI 
treatment within 1 month before rebiopsy. Here, 
patients who continued receiving EGFR-TKI 
treatment within 1 month before rebiopsy had a lower 
T790M mutation rate (P = 0.008). Additionally, 
patients who had received treatment other than 
EGFR-TKI between the first EGFR-TKI progression 
and rebiopsy also tended to have a lower T790M 
mutation rate, although this latter trend was not 
statistically significant (P = 0.076). 
Based on the results of the univariate analyses, 
we performed a multiple logistic regression analysis 
to confirm the factors affecting the emergence of 
T790M mutation (Table 4). Our results indicated that 
the exon 19 deletion was the most significant factor 
related to T790M mutation development (hazard ratio 
= 6.875, 95% confidence interval: 1.477–32.011, P = 
0.014). 
 
Table 3. Univariate analysis of the association of EGFR T790M 
mutation with rebiopsy condition and rebiopsy methods  
Characteristics n T790M mutation 
(%) 
P value 
Rebiopsy timing-1a   0.076 
 At first EGFR-TKI PD 22 12 (54.5)  
With interval from first 
EGFR-TKI PD 
19 6 (31.6)  
Rebiopsy timing-2   0.116 
 With EGFR-TKI treatment at 
rebiopsy 
17 13 (76.5)  
Without EGFR-TKI 
treatment at rebiopsy 
24 5 (20.8)  
Size of Target lesion (cm)b   0.551 
 <3 14 7 (50.0)  
 3-5 14 7 (50.0)  
 >5 11 3 (27.3)  
 unmeasurable lesionc 2 1 (50.0)  
Rebiopsy sites   0.123 
 Primary tumor 30 11 (36.7%)  
 Metastatic mediastinal 
lymph nodes 
11 7 (63.6%)  
EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; PD, 
progressive disease; TBLB, transbronchial lung biopsy; EBUS-TBNA, 
endobronchial ultrasound transbronchial aspiration. 
a Denote the 1st treated EGFR-TKI 
b Size of target lesion had been measured at rebiopsy 
c unmeasurable due to random biopsy of numerable lesions 
 
Table 4. Multivariate analysis of the factors affecting the 
emergence of EGFR T790M mutation. 
Variable T790M mutation 
HR 95% CI P value* 
Age, yr <60 1   
 ≥60 0.649 0.134-3.153 0.592 
Gender Male 1   
 Female 2.092 0.205-21.287 0.533 
Smoking 
status 
Never 1   
 Former and current 4.073 0.250-66.392 0.324 
Baseline EGFR 
mutations 
Exon 21 L858R or 
L861Q 
1   




treatment at rebiopsy 
1   
 With EGFR-TKI 
treatment at rebiopsy 
3.639 0.718-18.443 0.119 




Patients with EGFR-mutated NSCLC face the 
significant clinical issue of acquired resistance after 
EGFR-TKI treatment, and the EGFR T790M mutation 
is most prevalent among the currently identified 
resistance mechanisms[13, 14]. As mentioned in the 
Introduction, the importance of rebiopsy for patients 




with progressive cancer and a history of EGFR-TKI 
treatment has increased with the development and 
use of third-generation EGFR-TKIs, which inhibit 
both activating EGFR and resistant T790M mutations 
while sparing wild-type EGFR[15, 16]. Therefore, we 
investigated the usefulness of bronchoscopy for 
rebiopsy in these patients. 
We observed similar rates of practical rebiopsy 
success with bronchoscopy between our study and 
the reports of other studies of bronchoscopic rebiopsy. 
Specifically, bronchoscopy was found to be the most 
useful rebiopsy tool, as it yielded a high success rate 
and low incidence of complications. In most rebiopsy 
cases, a mutation analysis was performed to 
determine the therapeutic agent for lung 
adenocarcinoma. Because lung adenocarcinomas arise 
mostly in the lung parenchyma, rather than the 
endobronchus, rebiopsies are performed via 
bronchoscopy, percutaneous needle aspiration biopsy 
(PCNAB), or surgical resection, especially for 
peripheral lesions. Although percutaneous needle 
aspiration is highly successful when performed under 
imaging guidance, this technique does not collect 
sufficient tumor cells for a multiple mutation analysis 
and is associated with a relatively high risk of 
pneumothorax. In a rebiopsy study using CT-guided 
PCNAB, Yoon et al. reported an 80% rate of success 
regarding the collection of sufficient specimens for 
mutational analysis, but observed that 14% of patients 
suffered biopsy-related complications[17]. In another 
rebiopsy study using CT-guided core biopsy, the rate 
of adequate specimen acquisition was 90%, although 
20% of patients experienced biopsy-related 
complications[18].  
Surgical resection is contraindicated in patients 
with a poor performance status. However, 
transbronchial lung biopsy via bronchoscopy yields a 
larger amount of tumor cells compared to PCNAB, 
and confers a relatively low risk of pneumothorax. 
Although previous rebiopsy studies have reported 
lower success rates for transbronchial lung biopsy via 
bronchoscopy relative to those for PCNAB, the use of 
modalities such as electromagnetic navigation 
bronchoscopy, radial EBUS-GS (guide sheath) and 
virtual bronchoscopic navigation can enhance the 
success rate of bronchoscopic rebiopsy, particularly 
for small peripheral lung lesions. Notably, a rebiopsy 
study using EBUS-GS reported a rebiopsy success rate 
of 79.2%, similar to that reported in PCNAB studies, 
with no severe complications[19]. Another study 
using EBUS-GS for the diagnosis of peripheral 
pulmonary lesions reported a pneumothorax 
occurrence rate of <1%[20]. In addition, newest 
approaches to complement the weakness of 
bronchoscopic diagnosis of lung nodules have been 
introduced. TBLB using ultrathin bronchoscope 
showed higher diagnostic yield than conventional 
bronchoscope[21, 22]. Conebeam-CT guided TBLB 
showed twofold higher results than conventional 
methods for the diagnosis of peripheral nodules less 
than 20mm[23]. In addition, bronchoscopic 
trahnsparenchymal nodule access (BTPNA) has been 
attempted for nodules without “bronchus sign” 
(airway directly reading to nodules)[24, 25]. If these 
newest techniques are applied to rebiopsy, the 
diagnostic yield of bronchoscopic rebiopsy can be 
further improved and the role of bronchoscopy will 
be even greater in the rebiopsy area. 
In addition, transbronchial biopsy of the primary 
tumor and EBUS-TBNA of the metastatic mediastinal 
LN (i.e., multiple sites) can be performed 
simultaneously, which presents an advantage in 
terms of overcoming spatial intrathoracic T790M 
heterogeneity and enabling a careful analysis of the 
T790M status. In fact, 1 case in the present study did 
not harbor T790M in the primary lung tumor, whereas 
EBUS-TBNA revealed this mutation in the 
mediastinal LN. The patient was subsequently treated 
with a third-generation EGFR-TKI. Another study 
reported a higher T790M detection rate for the 
rebiopsy of metastatic lung lesions, compared with 
biopsy of primary tumors[18]. Similarly, our study 
found a higher T790M detection rate in the metastatic 
mediastinal lymph nodes (63.6%) than in primary 
tumors (36.7%), although this difference did not reach 
statistical significance. Although reports suggest that 
T790M detection does not correlate with the biopsy 
location[26, 27], biopsy of both the primary tumor and 
metastatic lung lesion could increase the detection 
rate. In summary, rebiopsy via bronchoscopy is 
minimally invasive and safely allows the 
simultaneous collection of sufficient amounts of 
tumor cells from multiple sites during a single 
procedure. Therefore, bronchoscopic rebiopsy is more 
appropriate than PCNAB as a means to overcome the 
considerable tumor heterogeneity observed in 
EGFR-TKI-treated patients with EGFR-mutant lung 
cancer. 
Liquid biopsy has recently been introduced for 
detecting the T790M mutation. This analysis of 
circulating tumor cells and cell-free circulating nucleic 
acids enables a more comprehensive assessment of 
tumor heterogeneity, identification of resistance 
mechanisms, and real-time monitoring of treatment 
responses in solid tumors[28]. However, the 
concordance rates of liquid biopsy with conventional 
biopsy still vary widely (50–83%) [29-32]. Given this 
uncertain reproducibility, liquid biopsy is not yet 
widely used in lung cancer patients in daily 
practice[33]. However, this is expected to change with 




the development of more sophisticated technologies. 
In addition, cell-free circulating nucleic acids can be 
obtained from sputum, pleural fluid, and 
bronchoalveolar lavage fluid (BALF), as well as 
plasma. Compared to plasma, BALF is expected to 
better reflect the tumor DNA status when evaluated 
using a tumor-derived extracellular vesicle isolation 
method[34], which is likely to increase in popularity 
in the future. Especially for the T790M detection by 
liquid biopsy, plasma EGFR assay was approved by 
FDA as a blood-based companion diagnostic for the 
osimertinib in 2016. Recent study shows that 
sensitivity of plasma T790M detection was 70% and 
an alternate paradigm was suggested that plasma 
genotyping for T790M would be used as a screening 
test before tissue biopsy[35]. But in the cases of 
plasma T790M negative, plasma cannot fully replace 
tissue biopsy because the false-negative rate is high 
up to 30%. So careful interpretation is needed in 
plasma T790M negative cases, and tissue biopsy must 
be performed to complement the plasma test.  
We additionally investigated the frequency of 
EGFR T790M among rebiopsies and observed a 
difference in the T790M emergence rate according to 
the initial EGFR mutation status. As shown in Figure 
2, the T790M emergence rate was highest among cases 
with exon 19 deletions (65%), and this group [18] had 
the longest median interval until T790M emergence 
(14.1 months). Similarly, in a previous study of 
Japanese patients, T790M more frequently emerged in 
patients with initial exon 19 deletions (55.6%) than in 
those with L858R mutations (43.0%) (P = 0.005)[11]. In 
another Japanese study, the T790M mutation was also 
more frequent in patients with an exon 19 deletion 
mutation (63%) than in those with a L858R mutation 
(38%) (P = 0.035)[36]. Other previous studies have 
shown similar trends. We attribute these findings to 
the tendency of cases involving exon 19 deletion to 
exhibit the most favorable responses and to receive 
EGFR-TKI treatment for longer durations, compared 
to cases with other EGFR mutations. Kuiper et al. 
reported that patients who developed T790M 
mutations after TKI therapy (detected via biopsy) had 
a longer median PFS, compared to T790M-negative 
patients (14.2 vs. 11.1 months, P = 0.034)[37]. Recently, 
Zou et al. investigated the underlying causes of high 
T790M expression in cases of exon 19 deletion using 
computational modeling and molecular dynamics 
simulations[38]. The authors reported that when 
compared with exon 19 non-LRE deletions or L858R 
mutation, a delE746_A750 mutation was associated 
with a higher probability of acquiring the T790M 
mutation after EGFR-TKI. Additionally, Zou and 
colleagues found that delE746_A750 exhibited lower 
stability around the residue T790M, compared with 
delS752_I759 and L858R, suggesting that this might 
explain the strong expression of T790M in cases of 
exon 19 deletion mutation. Together, these results 
suggest an association of initial EGFR mutation status 
and long-term EGFR-TKI exposure with T790M 
acquisition.  
This study has some limitations. Data were 
retrospectively analyzed and the number of study 
subjects was relatively small. However, it has the 
advantage of reflecting the practice using various type 
of bronchoscopic rebiopsy including endobronchial 
biopsy, transbronchial lung biopsy and EBUS-TBNA 
in the real-world conditions.  
Conclusions 
We have demonstrated the usefulness of 
bronchoscopic rebiopsy over other approaches. 
Additionally, we observed that the T790M emergence 
rate was highest among cases with exon 19 deletion, 
possibly attributable to long-term EGFR-TKI exposure 
in these cases. 
Clinical Practice Points 
• Rebiopsy has become essential for treatment 
guidance in patients with progressive lung 
adenocarcinoma and a previous history of 
EGFR-TKI therapy. 
• We assessed the advantages of flexible 
bronchoscopy as a rebiopsy method and the 
prevalence of and factors affecting the T790M 
mutation after EGFR-TKI failure. 
• The success rate of bronchoscopic rebiopsy was 
73.4%. The most common rebiopsy method was 
transbronchial lung biopsy (41.5%), followed by 
EBUS-TBNA (26.8%) and endobronchial biopsy 
(19.5%).  
• The T790M mutation was identified in 18 (43.9%) 
patients. The median interval to T790M 
emergence was the longest among cases with 
exon 19 deletion (14.1 months), followed by exon 
21 L858R or L861Q (11.3 months) and other rare 
EGFR mutations (2.9 months). 
• The T790M emergence rate was highest in cases 
with exon 19 deletion (65%), likely as a 
consequence of long-term EGFR-TKI exposure. 
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